文献速递头颈外科

循环肿瘤DNA作为头颈癌治疗后PET的辅助手段用于复发风险评估

ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment.
PubMed 文献 · Otolaryngol Head Neck Surg · 2024-04-09

这项回顾性单机构研究纳入29例根治性治疗后的头颈鳞状细胞癌患者,在治疗后1至3、6、9、12个月检测ctDNA。7例检出ctDNA者全部复发;ctDNA检测复发风险比为9.94(95%CI 1.56-63.3,P=.015),特异度100%、敏感度78%。作者认为ctDNA可作为治疗后PET的辅助检查。

要点

  • 治疗后ctDNA检出者7例,全部出现疾病复发。
  • ctDNA检出与复发风险升高相关:HR 9.94(95%CI 1.56-63.3,P=.015)。
  • ctDNA敏感度78%、特异度100%,PET敏感度78%、特异度68%。

核心结论

  • 作者认为,基于本研究数据,ctDNA可作为治疗后PET的优良辅助检查,并可在PET结果不确定、难以解读时帮助指导医师。

研究设计与样本

  • 回顾性单机构研究,在大学医院开展。
  • 纳入2021年8月至2023年1月接受根治性治疗的头颈鳞状细胞癌(HNSCC)患者29例。
  • 在根治性治疗后1至3、6、9、12个月分析ctDNA水平。
  • 采用个体化、肿瘤信息指导的多重聚合酶链反应(PCR)下一代测序(NGS)检测ctDNA水平。
  • 主要结局为无复发生存概率(RFP),次要结局为总生存(OS)、敏感度、特异度、阴性预测值(NPV)与阳性预测值(PPV)。

主要发现

  • 患者中位年龄65岁(四分位距56-69),男性22例(76%)。
  • 原发部位为喉12例、口咽10例、口腔6例。
  • 治疗后检出ctDNA者7例,全部出现疾病复发。
  • 治疗后ctDNA检出与疾病复发风险升高相关:风险比9.94(95%CI 1.56-63.3,P=.015)。
  • ctDNA识别复发的敏感度为78%、特异度为100%,NPV为91%、PPV为100%;PET敏感度为78%、特异度为68%,NPV为86%、PPV为54%。

临床怎么用

  • 作者认为ctDNA可作为治疗后PET的优良辅助检查。
  • 作者认为在PET结果不确定、难以解读的病例中,ctDNA可帮助指导医师。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Circulating tumor DNA (ctDNA) detection is an emerging technique that identifies minimal residual disease in patients with solid tumors. ctDNA can act as an adjunct method to help overcome the limitations of positron emission tomography (PET) and select patients who are at high risk for recurrence. STUDY DESIGN: Retrospective Single Institutional Study. SETTING: University Hospital Setting. METHODS: Twenty-nine patients who underwent definitive treatment for squamous cell carcinoma of the head and neck (HNSCC) from 8/2021 to 01/2023 had ctDNA levels analyzed at 1 to 3, 6, 9, and 12 months after definitive treatment. A personalized, tumor-informed, multiplex polymerase chain reaction (PCR) next-generation sequencing (NGS) assay was used to detect the ctDNA levels. The primary outcome was recurrence-free probability (RFP), and the secondary outcomes were overall survival (OS), sensitivity, specificity, and the test's negative (NPV) and positive predictive values (PPV). RESULTS: The median age of patients was 65 years (interquartile range: 56-69), with majority being males (n = 22, 76%). The primary sites were larynx (n = 12), oropharynx (n = 10), and oral cavity (n = 6). Posttreatment ctDNA was detected in 7 patients, all of whom had disease recurrence. ctDNA detection after definitive treatment was associated with a higher risk of disease recurrence (hazard ratio: 9.94, 95% confidence interval: 1.56-63.3, P = .015). ctDNA identified recurrence with 100% specificity and 78% sensitivity. The NPV and PPV were 91% and 100%. PET had 78% sensitivity but only 68% specificity with 86% NPV, and 54% PPV. CONCLUSION: Based on our data, ctDNA can be an excellent adjunct test for posttreatment PET and can help guide physicians in cases where PET results are inconclusive and difficult to interpret.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Lele SJ, Adilbay D, Lewis E, et al. ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment. Otolaryngol Head Neck Surg. 2024. PMID: 38591659. doi:10.1002/ohn.760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。